United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Gilead Sciences, Second Genome form IBD drug discovery alliance Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second… bypharmanewsdailyApril 9, 2020
